GARAŽA forum

"There is no world, I think, where [the effectiveness] is the same level . . . we had with [the] Delta [variant],” Bancel told the Financial Times in an interview at the company’s headquarters in Cambridge, Massachusetts. He added: “I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . . are like, ‘This is not going to be good’.”

Moderna and Pfizer are now working on new vaccines to target the Omicron variant, which the World Health Organization has said poses a “very high risk”. (...) Bancel said data indicating how existing vaccines performed against the Omicron variant, and whether it caused severe disease, should become available within two weeks. But he said it would take several months before an Omicron-specific vaccine could be produced at scale, and suggested there might be a case for giving more potent boosters to the elderly or people with compromised immune systems in the meantime.

blaugrana napisao: 30 Nov 2021, 10:21 U Nemacku, odnosno Minhen je dosao letom iz J. Afrike.
Posle toga jos jedan slucaj u Frankfurtu, takodje avion.

Gesendet von meinem Blaulaxy mit Tapatalk

brabonjak napisao: 30 Nov 2021, 11:24 Preprint u The Lancetu: Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study

Velika studija efikasnosti vakcina u Švedskoj, koja još nije peer review-ovana. Postavljam grafike efikasnosti po danima od potpune vakcinacije protiv teške kliničke slike, kao i protiv bilo kakve infekcije. U pdf-u koji može da se preuzme sa navedenog linka ima detaljno po proizvođaču vakcine (Pfizer, Moderna, AZ), starosti i proteklom vremenu od potpune vakcinacije pa, koga zanima, može da se pronađe i vidi gde otprilike sada stoji. Ovo sivo je 95-oprocentni interval sigurnosti.

Koliko je meni poznato, po prvi put nailazimo na to da postoji ozbiljna šansa potpuno vakcinisani posle 6, 7 meseci od vakcinacije imaju veći rizik od zaražavanja i razvijanja teže kliničke slike od nevakcinisanih.

ADE occurs when the antibodies generated during an immune response recognize and bind to a pathogen, but they are unable to prevent infection. Instead, these antibodies act as a “Trojan horse,” allowing the pathogen to get into cells and exacerbate the immune response.

Importantly, when a vaccinated person subsequently gets infected, this is not automatically evidence of ADE. Specifically, if a vaccinated person gets infected with the pathogen against which the vaccine protects, three different scenarios can occur:

Mild illness – In this scenario, the person may experience some symptoms, but they are more of an inconvenience and last only a few days (typically about 1-3 days). For many respiratory and gastrointestinal infections (e.g., influenza, COVID-19, and rotavirus), this is common. These mild symptoms are evidence that the vaccine worked.
“Breakthrough illness” – Traditionally, this term has been reserved for vaccinated people who get more severely ill, requiring hospitalization or experiencing untoward outcomes, such as disease complications (e.g., pneumonia) or death. In this case, the vaccine may not have worked at all or it did not induce high enough levels of immunity to effectively stop an infection.
ADE – In this scenario, the antibodies that the vaccine generated actually help the virus infect greater numbers of cells than it would have on its own. In this situation, the antibodies bind to the virus and help it more easily get into cells than it would on its own. The result is often more severe illness than if the person had been unvaccinated. ADE can occur after disease and has on occasion been identified following vaccination, as described below. Any vaccine that has been found to cause ADE has stopped being used or, more recently as described below for dengue vaccine, been recommended only for those who will not be affected by ADE. Evidence of ADE has not emerged for COVID-19 vaccines even though concerns have been raised.

Bax napisao:

brabonjak napisao: 30 Nov 2021, 11:24 Preprint u The Lancetu: Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study

Velika studija efikasnosti vakcina u Švedskoj, koja još nije peer review-ovana. Postavljam grafike efikasnosti po danima od potpune vakcinacije protiv teške kliničke slike, kao i protiv bilo kakve infekcije. U pdf-u koji može da se preuzme sa navedenog linka ima detaljno po proizvođaču vakcine (Pfizer, Moderna, AZ), starosti i proteklom vremenu od potpune vakcinacije pa, koga zanima, može da se pronađe i vidi gde otprilike sada stoji. Ovo sivo je 95-oprocentni interval sigurnosti.

Koliko je meni poznato, po prvi put nailazimo na to da postoji ozbiljna šansa potpuno vakcinisani posle 6, 7 meseci od vakcinacije imaju veći rizik od zaražavanja i razvijanja teže kliničke slike od nevakcinisanih.

Nije to prvi put, mislim da se nesto slicno desavalo sa vakcinama za Sras1 virus. Takodje mislim da je i Zika veci problem pravio reinficiranima, ima i neki naziv za te efekte ADE, moze da se istrazi malo dalje ta prica ako te zanima....

ADE occurs when the antibodies generated during an immune response recognize and bind to a pathogen, but they are unable to prevent infection. Instead, these antibodies act as a “Trojan horse,” allowing the pathogen to get into cells and exacerbate the immune response.

Importantly, when a vaccinated person subsequently gets infected, this is not automatically evidence of ADE. Specifically, if a vaccinated person gets infected with the pathogen against which the vaccine protects, three different scenarios can occur:

Mild illness – In this scenario, the person may experience some symptoms, but they are more of an inconvenience and last only a few days (typically about 1-3 days). For many respiratory and gastrointestinal infections (e.g., influenza, COVID-19, and rotavirus), this is common. These mild symptoms are evidence that the vaccine worked.
“Breakthrough illness” – Traditionally, this term has been reserved for vaccinated people who get more severely ill, requiring hospitalization or experiencing untoward outcomes, such as disease complications (e.g., pneumonia) or death. In this case, the vaccine may not have worked at all or it did not induce high enough levels of immunity to effectively stop an infection.
ADE – In this scenario, the antibodies that the vaccine generated actually help the virus infect greater numbers of cells than it would have on its own. In this situation, the antibodies bind to the virus and help it more easily get into cells than it would on its own. The result is often more severe illness than if the person had been unvaccinated. ADE can occur after disease and has on occasion been identified following vaccination, as described below. Any vaccine that has been found to cause ADE has stopped being used or, more recently as described below for dengue vaccine, been recommended only for those who will not be affected by ADE. Evidence of ADE has not emerged for COVID-19 vaccines even though concerns have been raised.

Bax napisao:

blaugrana napisao: 30 Nov 2021, 10:21 U Nemacku, odnosno Minhen je dosao letom iz J. Afrike.
Posle toga jos jedan slucaj u Frankfurtu, takodje avion.

Gesendet von meinem Blaulaxy mit Tapatalk

Omikron je bio u Holandiji ranije nego što se ranije mislilo

Omikron je već bio u Holandiji pre nego što je varijanta korone pronađena u uzorcima uzetim od putnika koji su se vraćali iz Južne Afrike u petak. RIVM saopštava da je institut pronašao varijantu u dva testna uzorka koja su uzeta iz GGD 19. i 23. novembra.

„Prošlog četvrtka dobili smo poruke iz Južne Afrike o ovoj novoj varijanti“, kaže virolog Šantal Rejsken iz RIVM-a na NPO Radiju 1. ukazuje na to da li je ova varijanta možda prisutna u Holandiji. Juče se ispostavilo da je tako.

Veza sa Južnom Afrikom još nije poznata

Sada se istražuje da li su dva nova slučaja povezana ili su u pitanju odvojeni slučajevi. GGD vodi istrage o izvorima i kontaktima. Prema Reuskenu, takođe još nije jasno da li postoji veza sa Južnom Afrikom. Ona očekuje više informacija o tome danas.

Ako ta dva čoveka nisu imala kontakt sa južnom Afrikom, to ne znači da varijanta ne dolazi odatle. „Možda su imali kontakt sa nekim ko je već nosio varijantu omikrona i kao rezultat toga se zarazio“, rekao je Reusken.

Možda već širu distribuciju u Holandiji

Laboratorije koje su otkrile poslednja dva slučaja sada ispituju materijal pozitivnih testova pre tri meseca. Ovo bi moglo otkriti još više infekcija sa varijantom omikron, koje su se takođe mogle desiti ranije nego u sada poznatim slučajevima.

Ako je to slučaj, omikron bi se već mogao znatno proširiti Holandijom. „Pretpostavljamo da se zaraženi pridržavaju karantinskih pravila“, kaže Reuskens, „ali svi znamo da ponekad postoje i infekcije bez simptoma, tako da je to svakako moguće“.

Inficirani odvojeno jedan od drugog

Malo više se saznalo i o četrnaest infekcija omikron varijantom ljudi koji su se u petak vratili iz Južne Afrike, kaže Reusken. „Ako pogledate gradivne blokove virusa, možete videti da je to omikron varijanta, ali takođe možete videti da postoji određeni stepen razlike između tih virusa.

Iz ovoga se može zaključiti da su se „ljudi posebno zarazili” pre nego što su ušli u avion.